Exploring analytical assays and CMC challenges for viral vector-based therapies

Abi Pinchbeck, Editor, Cell & Gene Therapy Insights, speaks to Vladimir Slepushkin, Chief Technology Officer, MedTherapy Biotechnology, to explore the state of the art and novel tools in lentiviral and AAV analytics and CMC. They discuss the delicate interconnectivity between the upstream and downstream, the need for global regulatory harmonization for advanced therapies, and the importance of developing processes and assays simultaneously.

Please enter your email to access content Read now